Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 42-47

  Civera, Miguel ^a   Merchante, Angel ^a   Salvador, María ^a   Sanz, Javier ^a   Martínez, Isidoro ^a  

^a HOSPITAL LLUÍS ALCANYÍS   (Spain)

Author keywords

Glycemic control; Metformin; NPH insulin; Repaglinide; Type 2 diabetes

Indexed keywords

DIANBEN; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; ISOPHANE INSULIN; METFORMIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPAIN; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN, ISOPHANE; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; PROSPECTIVE STUDIES; SAFETY; WEIGHT GAIN;

EID: 37549051276     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.07.001     Document Type: Article

References (22)

1. Harris M.I. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 23 (2002) 734-738
2. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
3. A.N. Goudswaard, N.J. Furlong, G.D. Valk, R.P. Stolk, G.E.H.M. Rutten, Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus, The Cochrane Database of Systematic Reviews 2004, Issue 4, Art. No.: CD003418.pub2, doi:10.1002/14651858. CD003418.pub2.
4. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes, International Diabetes Federation, Brussels, 2005.
5. Meigs J.B., Nathan Sr. D.M., D'Agostino R.B., and Wilson P.W. Fasting and postchallenge glycemic and cardiovascular risk: the framingham offspring study. Diabetes Care 25 (2002) 1840-1850
6. Ceriello A. Postprandial hyperglycemia and diabetes complications. Is it time to treat?. Diabetes 54 (2005) 1-7
7. American Diabetes Association. Standards of medical care in diabetes (Position Statement). Diabetes Care 29 Suppl. 1 (2006) S4-S42
8. Guay D.R. Repaglinide, a novel short-acting, hypoglycaemia agent for type 2 diabetes mellitus. Pharmacotherapy 18 (1998) 1195-1204
9. De Luis D.A., Aller R., Cuellar L., Terroba C., Ovalle H., Izaola O., et al. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 24 (2001) 1844-1845
10. Furlong N.J., Hulme S.A., O'Brien S.V., and Hardy K.J. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 25 (2002) 1685-1690
11. Furlong N.J., Hulme S.A., O'Brien S.V., and Hardy K.J. Comparison of repaglinide vs. glicazide in combination with bedtime insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet. Med. 20 (2003) 935-941
12. Panelo A., Wing J.R., and AGEE-1272 Study Group. Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin. Diabetes Care 28 (2005) 1789-1790
13. Declaration of Helsinki. Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 277 (1997) 925-926
14. Raccah D., Hanaire-Broutin H., Sert-Langeron C., Brin S., Chabrier G., Fontaine P.M., et al. Insulin initiation in type 2 diabetic patients admitted in hospital in France and follow-up at 1 year. Diabetes Metab. 32 (2006) 224-250
15. Yki-Järvinen H., Ryysy L., Nikkilä K., Tulokas T., Vanamo R., and Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann. Intern. Med. 130 (1999) 389-396
16. Riddle M.C., Rosenstock J., and Jerich J. The insulin glargine 4002 study investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
17. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., and Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
18. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Daile G. The insulin glargine 4014 study investigators: triple therapy in type 2 diabetes. Diabetes Care 29 (2006) 554-559
19. Jacober S.J., Scim-Bacon J.L., and Zagar A.J. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 receiving oral antidiabetes agents. Diabetes Obes. Metab. 8 (2006) 448-455
20. Aljabri K., Kozak S.E., and Thompson D.M. Addition of pioglitazone or bedtime insulin to maximal dose of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am. J. Med. 116 (2004) 230-235
21. Damsbo P., Clauson P., Marbury T.C., and Winfeld K. A double-blind randomized comparison of meal-related glycaemic control by repaglinide and glyburide in well controlled type 2 diabetic patients. Diabetes Care 24 (1999) 780-794
22. Yki-Järvinen H., Dressler A., Ziemen M., and The HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136